General
Preferred name
ILOPERIDONE
Synonyms
Iloperidone (hydrochloride) ()
HP 873 hydrochloride ()
HP 873 ()
iloperidone injection ()
HP873 ()
Fanapt ()
HP-873 ()
Iloperidone-d3 ()
P&D ID
PD009344
CAS
133454-47-4
1071167-49-1
Tags
natural product
drug
available
Approved by
FDA
First approval
2009
Drug Status
approved
Drug indication
Antipsychotic
Schizophrenia
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION
Well absorbed from the GI tract and Cmax is reached within 2-4 hours.; Steady-state concentration is achieved in 3-4 days post-administration of iloperidone. Relative bioavailability of the tablet formulation compared to oral solution is 96%. Accumulation occurs in a predictable fashion.
MOA
Iloperidone is a dopamine D2 and 5-HT2A receptor antagonist and acts as a neuroleptic agent. ; ;
DESCRIPTION
Iloperidone is an atypical antipsychotic drug.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
24
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
42
Molecular Weight
426.2
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
8
Ring Count
4
Aromatic Ring Count
3
cLogP
4.83
TPSA
64.8
Fraction CSP3
0.42
Chiral centers
0.0
Largest ring
6.0
QED
0.38
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Dopamine Receptor
5-HT Receptor
??-adrenergic receptor
dopamine
ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7
Atypical antipsychotic
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Indication
schizophrenia
MOA
dopamine receptor antagonist, serotonin receptor antagonist
Source data
